Collaborative Arrangements - Development and Commercialization Agreement (Details) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 30, 2015	Feb. 28, 2015 USD ($) $ / shares shares	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) item	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Collaborative Arrangements
Equity investments made in the entity					$ 253,028	$ 79,017
Revenue from collaborative arrangements					31,045	32,718	$ 7,270
Total reduction to R&D expense					90,737	55,156	1,884
Mylan
Collaborative Arrangements
Total reduction to R&D expense					83,500
Mylan | Maximum
Collaborative Arrangements
Potential development, regulatory and sales milestone payments					205,000
Mylan | Revefenacin
Collaborative Arrangements
Potential development, regulatory and sales milestone payments					160,000
Potential commercialization milestone payments					150,000
Potential regulatory milestone payments					10,000
Mylan | Future Potential Combination Products
Collaborative Arrangements
Potential development, regulatory and sales milestone payments					45,000
Mylan
Collaborative Arrangements
Revenue from collaborative arrangements					15,102	19,175	0
Milestone payment(s) received					15,000
Total reduction to R&D expense					$ 83,490	52,551	0
Achievement in enrollment (as a percent)					50.00%
Mylan | Purchase Agreement
Collaborative Arrangements
Equity investments made in the entity		$ 30,000
Number of shares purchased | shares		1,585,790
Share Price | $ / shares		$ 18.918
Price per share premium (as a percent)		10.00%
Trading days	5 days
Premium proceeds from sale of ordinary shares				$ 4,200
Mylan | Development and Commercialization Agreement
Collaborative Arrangements
Initial cash payment			$ 15,000	15,000
Payments received				$ 19,200
Units of accounting | item					3
Takeda Pharmaceuticals
Collaborative Arrangements
Revenue from collaborative arrangements					$ 15,075	0	0
Trek Therapeutics
Collaborative Arrangements
Revenue from collaborative arrangements					0	8,216	0
Trek Therapeutics | TD-6450
Collaborative Arrangements
Revenue from collaborative arrangements					15,100
Other
Collaborative Arrangements
Revenue from collaborative arrangements					500	0	0
Total reduction to R&D expense					$ 134	$ 483	$ 120